Seaport Therapeutics doses first patient in Phase 2a GAAD trial

BOSTON--()--October 07, 2026-- PureTech Health plc (LSE: PRTC) ("PureTech" or the "Company"), a hub-and-spoke biotherapeutics company dedicated to giving life to science and transforming innovation into value, notes that its Founded Entity, Seaport Therapeutics, today announced that the first patient has been dosed in a Phase 2a clinical trial in Australia evaluating GlyphAgo(TM) (SPT-320 or Glyph Agomelatine) in adults with generalized anxiety disorder ("GAD") and sleep disturbance. The six-week trial is designed to establish proof-of-pharmacology by evaluating the effects of GlyphAgo on sleep. Seaport expects to report topline data from the trial in early 2028. GlyphAgo is a novel, "Glyphed" oral prodrug of agomelatine, a clinically validated MT1/MT2 melatonin receptor agonist and serotonin 2C (5-HT2C) receptor antagonist. Agomelatine has demonstrated statistically significant separation from placebo in four third-party placebo-controlled studies in GAD.(1) Based on published meta-analyses using indirect comparisons across placebo-controlled trials, agomelatine ranked highest for efficacy and tolerability relative to benzodiazepines and selective serotonin-reuptake inhibitors (SSRIs),(2) which are standard-of-care drugs for GAD. Seaport also plans to initiate a global, randomized, double-blind, placebo-controlled Phase 2/3 clinical trial evaluating the efficacy and safety of GlyphAgo in patients with GAD in the first half of 2027. Seaport expects topline data from the Phase 2/3 trial by the end of 2028. The full text of the announcement from Seaport is as follows: Seaport Therapeutics Announces First Patient Dosed in Phase 2a Clinical Trial Evaluating GlyphAgo(TM) in Patients with Generalized Anxiety Disorder and Sleep Disturbance Trial is designed to demonstrate proof-of-pharmacology by evaluating the effects of GlyphAgo on sleep and anxiety symptoms in patients with generalized anxiety disorder In Phase 1, GlyphAgo demonstrated a statistically significant 6.8-fold increase in bioavailability compared to unmodified agomelatine, achieving therapeutically relevant exposures of agomelatine at doses designed to reduce liver exposure Topline data from the Phase 2a clinical trial are expected in early 2028 BOSTON, Oct. 7, 2026 -- Seaport Therapeutics, Inc., (Nasdaq: SPTX) ("Seaport" or the "Company"), a clinical-stage therapeutics company that is inventing and developing novel neuropsychiatric medicines, today announced that the first patient has been dosed in a Phase 2a clinical trial in Australia evaluating GlyphAgo(TM) (SPT-320 or Glyph Agomelatine), in adults with generalized anxiety disorder ("GAD") and sleep disturbance. GlyphAgo is a novel, "Glyphed" oral prodrug of agomelatine, a clinically validated MT1/MT2 melatonin receptor agonist and serotonin 2C (5-HT2C) receptor antagonist. Agomelatine has demonstrated statistically significant separation from placebo in four third-party placebo-controlled studies in GAD(1). Based on publishe